Dr Urano's work on Wolframs which could lead to a
Post# of 30028
Posted On: 08/18/2014 9:04:45 PM
Dr Urano's work on Wolframs which could lead to a cure of diabetes could lead to huge revenue potential for AMBS down the road: Last paragraph notes some major players in the field (Potential partners in the diabetes space) With Urano's tweet today, I'm only speculating that it had something to do with positive Wolfram's news!
According to a new market report published by Transparency Market Research, "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011 - 2018," the global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is expected to reach USD 98.4 billion in 2018, growing at a CAGR of 9.9% from 2011 to 2018.
In the overall global market, North America accounted for the highest share worth USD 19.9 billion in 2011 followed by Europe. However, with the continuous population and economic growth of the Asia-Pacific region, especially India and China, it is expected to witness the highest growth rate in the next six years.
Today, diabetes is one of the major areas of concern worldwide. The rising number of patients is due to the ever increasing population around the globe mainly in the Asia Pacific region. Currently, over 370 million people suffer from diabetes across the globe, which is expected to exceed 550 million by 2030. As of now, the age bracket of 40-59 years is the most affected diabetes population followed by the age group of 60-79 years. However, the age group of 60-79 years is expected to account for the highest number of diabetes patients by 2030.
The global diabetes therapeutics devices and drugs market is expected to reach USD 72.4 billion by 2018, growing at a CAGR of 10.4% from 2011 to 2018, whereas the global diagnosis and monitoring devices market is expected to reach USD 26.0 billion by 2018, growing at a CAGR of 7.8% for the same period.
Some of the major players in the diabetes devices and drugs market are Novo Nordisk, Sanofi, Roche, LifeScan, Takeda, Medtronic, Ell Lilly, Abbott Laboratories and Bayer Healthcare, among others. Novo Nordisk accounted for the largest share
According to a new market report published by Transparency Market Research, "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011 - 2018," the global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is expected to reach USD 98.4 billion in 2018, growing at a CAGR of 9.9% from 2011 to 2018.
In the overall global market, North America accounted for the highest share worth USD 19.9 billion in 2011 followed by Europe. However, with the continuous population and economic growth of the Asia-Pacific region, especially India and China, it is expected to witness the highest growth rate in the next six years.
Today, diabetes is one of the major areas of concern worldwide. The rising number of patients is due to the ever increasing population around the globe mainly in the Asia Pacific region. Currently, over 370 million people suffer from diabetes across the globe, which is expected to exceed 550 million by 2030. As of now, the age bracket of 40-59 years is the most affected diabetes population followed by the age group of 60-79 years. However, the age group of 60-79 years is expected to account for the highest number of diabetes patients by 2030.
The global diabetes therapeutics devices and drugs market is expected to reach USD 72.4 billion by 2018, growing at a CAGR of 10.4% from 2011 to 2018, whereas the global diagnosis and monitoring devices market is expected to reach USD 26.0 billion by 2018, growing at a CAGR of 7.8% for the same period.
Some of the major players in the diabetes devices and drugs market are Novo Nordisk, Sanofi, Roche, LifeScan, Takeda, Medtronic, Ell Lilly, Abbott Laboratories and Bayer Healthcare, among others. Novo Nordisk accounted for the largest share
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼